CAM
NAUT icon

Crown Advisors Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Crown Advisors Management’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$388K – 45
2026
Q1 		$388K Buy
+100,000
New +$246K 0.26% 39
2022
Q3 		– Sell
-250,000
Closed -$672K – 48
2022
Q2 		$672K Buy
+250,000
New +$931K 0.62% 42

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Crown Advisors Management's NAUT Position: Q2 2026 in Review

Crown Advisors Management sold out of Nautilus Biotechnolgy (NAUT) in Q2 2026, closing a stake of 100,000 shares — an estimated $388K sold.

Crown Advisors Management first reported a position in NAUT in Q2 2022 and held it in 2 quarters. The position peaked at $672K in Q2 2022. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Crown Advisors Management reported no remaining Nautilus Biotechnolgy position as of Q2 2026 after selling out during the quarter.
  • Crown Advisors Management sold 100,000 Nautilus Biotechnolgy shares in Q2 2026, an estimated $388K.
  • Crown Advisors Management first reported a position in Nautilus Biotechnolgy in Q2 2022 and held it in 2 quarters.
  • Crown Advisors Management's Nautilus Biotechnolgy position peaked at $672K in Q2 2022.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Crown Advisors Management's 13F filing for Q2 2026, filed 7 Aug 2026.